Analysts at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) in a research report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Brainstorm Cell Therapeutics Price Performance
BCLI stock opened at $0.39 on Thursday. Brainstorm Cell Therapeutics has a 12-month low of $0.13 and a 12-month high of $2.21. The firm has a market cap of $27.42 million, a PE ratio of -1.22 and a beta of 0.43. The business has a 50 day moving average of $0.47 and a 200-day moving average of $0.41.
Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02. On average, research analysts expect that Brainstorm Cell Therapeutics will post -0.28 earnings per share for the current year.
Institutional Investors Weigh In On Brainstorm Cell Therapeutics
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
Recommended Stories
- Five stocks we like better than Brainstorm Cell Therapeutics
- Want to Profit on the Downtrend? Downtrends, Explained.
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- What Are Dividend Challengers?
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.